George Tsey Sabblah, Katja Taxis, Mahama Duwiejua, Seth Kwaku Seaneke, Eugène van Puijenbroek, Florence van Hunsel
{"title":"实现患者参与药物警戒:从高收入国家到中低收入国家,重点是非洲。","authors":"George Tsey Sabblah, Katja Taxis, Mahama Duwiejua, Seth Kwaku Seaneke, Eugène van Puijenbroek, Florence van Hunsel","doi":"10.1080/14740338.2024.2416916","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Patient engagement in pharmacovigilance (PEP) has been shown to improve information on adverse drug reactions (ADRs), which may not be found in reports from healthcare professionals. This review shows that there is paucity of information on PEP in lower-middle-income countries (LMICs), particularly Africa. It provides insights into PEP in high-income countries (HICs) compared with Africa to help identify the disparities and system challenges in Africa.</p><p><strong>Areas covered: </strong>We discussed the impact of PEP in HICs in comparison with Africa and incorporated two case studies: PEP in Ghana and medication error reporting in Africa using a scoping review. Recommendations were made to improve medication safety in Africa based on the identified disparities and system challenges.</p><p><strong>Expert opinion: </strong>PEP is at an early stage in LMICs, particularly in Africa, with limited information available regarding patients' contributions to the safety of medicines. There should be further research into patients' roles in pharmacovigilance accompanied by advocacy efforts with policymakers, the development of sustainable funding strategies, benchmarking against experienced pharmacovigilance centers, and the use of technology to improve patient reporting.</p>","PeriodicalId":12232,"journal":{"name":"Expert Opinion on Drug Safety","volume":" ","pages":"1-9"},"PeriodicalIF":3.0000,"publicationDate":"2024-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Achieving patient engagement in pharmacovigilance: from high-income countries to lower and -middle-income countries with focus on Africa.\",\"authors\":\"George Tsey Sabblah, Katja Taxis, Mahama Duwiejua, Seth Kwaku Seaneke, Eugène van Puijenbroek, Florence van Hunsel\",\"doi\":\"10.1080/14740338.2024.2416916\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Patient engagement in pharmacovigilance (PEP) has been shown to improve information on adverse drug reactions (ADRs), which may not be found in reports from healthcare professionals. This review shows that there is paucity of information on PEP in lower-middle-income countries (LMICs), particularly Africa. It provides insights into PEP in high-income countries (HICs) compared with Africa to help identify the disparities and system challenges in Africa.</p><p><strong>Areas covered: </strong>We discussed the impact of PEP in HICs in comparison with Africa and incorporated two case studies: PEP in Ghana and medication error reporting in Africa using a scoping review. Recommendations were made to improve medication safety in Africa based on the identified disparities and system challenges.</p><p><strong>Expert opinion: </strong>PEP is at an early stage in LMICs, particularly in Africa, with limited information available regarding patients' contributions to the safety of medicines. There should be further research into patients' roles in pharmacovigilance accompanied by advocacy efforts with policymakers, the development of sustainable funding strategies, benchmarking against experienced pharmacovigilance centers, and the use of technology to improve patient reporting.</p>\",\"PeriodicalId\":12232,\"journal\":{\"name\":\"Expert Opinion on Drug Safety\",\"volume\":\" \",\"pages\":\"1-9\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-10-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Expert Opinion on Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14740338.2024.2416916\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14740338.2024.2416916","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
简介:事实证明,患者参与药物警戒 (PEP) 可以改善药物不良反应 (ADR) 的信息,而这些信息可能无法在医疗保健专业人员的报告中找到。本综述显示,在中低收入国家(LMIC),尤其是非洲,有关药物警戒的信息很少。与非洲相比,本综述对高收入国家(HICs)的 PEP 进行了深入探讨,以帮助确定非洲的差异和系统挑战:我们讨论了与非洲相比,PEP 在高收入国家/地区的影响,并纳入了两个案例研究:我们讨论了高收入国家与非洲的 PEP 影响,并纳入了两个案例研究:加纳的 PEP 和非洲的用药错误报告。根据已确定的差异和系统挑战,提出了改善非洲用药安全的建议:专家意见:PEP 在低收入与中等收入国家(尤其是非洲)尚处于早期阶段,有关患者对用药安全的贡献的信息十分有限。应进一步研究患者在药物警戒中的作用,同时向政策制定者进行宣传,制定可持续的资助战略,以经验丰富的药物警戒中心为基准,并利用技术改善患者的报告情况。
Achieving patient engagement in pharmacovigilance: from high-income countries to lower and -middle-income countries with focus on Africa.
Introduction: Patient engagement in pharmacovigilance (PEP) has been shown to improve information on adverse drug reactions (ADRs), which may not be found in reports from healthcare professionals. This review shows that there is paucity of information on PEP in lower-middle-income countries (LMICs), particularly Africa. It provides insights into PEP in high-income countries (HICs) compared with Africa to help identify the disparities and system challenges in Africa.
Areas covered: We discussed the impact of PEP in HICs in comparison with Africa and incorporated two case studies: PEP in Ghana and medication error reporting in Africa using a scoping review. Recommendations were made to improve medication safety in Africa based on the identified disparities and system challenges.
Expert opinion: PEP is at an early stage in LMICs, particularly in Africa, with limited information available regarding patients' contributions to the safety of medicines. There should be further research into patients' roles in pharmacovigilance accompanied by advocacy efforts with policymakers, the development of sustainable funding strategies, benchmarking against experienced pharmacovigilance centers, and the use of technology to improve patient reporting.
期刊介绍:
Expert Opinion on Drug Safety ranks #62 of 216 in the Pharmacology & Pharmacy category in the 2008 ISI Journal Citation Reports.
Expert Opinion on Drug Safety (ISSN 1474-0338 [print], 1744-764X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of drug safety and original papers on the clinical implications of drug treatment safety issues, providing expert opinion on the scope for future development.